Session Abstract – PMWC 2020 Silicon Valley


Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informing for the process from discovery to new indications, clinical trial design and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE data to better understand the patient populations using their drugs and the respective outcomes and to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.

 Session Chair Profile

Ph.D., Senior Vice President, Head QIAGEN Digital Insights, QIAGEN

Biography
Jonathan Sheldon leads QIAGEN's growing presence in bioinformatics, enabling customers to transform raw data from biological samples into valuable molecular insights. Dr. Sheldon came to QIAGEN from Oracle, where he was Global Vice President leading Oracle's Healthcare business globally in the Health Sciences Global Business Unit and served on the executive committee. Previously, he established the bioinformatics group and served as Head of Bioinformatics at Roche (UK) Pharmaceuticals, as well as providing leadership in software firms serving the life science and healthcare sectors. He serves on the Board of Directors of the Drug Information Association (DIA). He received his B.Sc. in Biochemistry and Molecular Biology from the University of Manchester, and his Ph.D. in Biochemistry and Molecular Biology from the University of Cambridge.


 Speaker Profile

PMWC LUMINARY AWARD
Leader and visionary entrepreneur in precision genomic diagnostics

Ph.D., Inventor, MammaPrint; Professor of Laboratory Medicine, Dir. Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center

Biography
Dr. van ‘t Veer is a world renowned molecular biologist whose research focuses on precision medicine to advance patient management based on knowledge of the genetic makeup of the tumor and the patient. As inventor of MammaPrint she has made a seminal impact on “rightsizing” the treatment of breast cancer and on molecular genomics. A recent publication in the New England Journal of Medicine on the MINDACT trial shows that 46% of breast cancer patients who are clinically high risk and considered for chemotherapy, can safely forgo this treatment based on a Low Risk MammaPrint result. Prior to joining UCSF she served as the head of diagnostic oncology at The Netherlands Cancer Institute. Dr. van ‘t Veer is the Biomarker Committee Chair for the Foundation of NIH- sponsored multicenter adaptive clinical trial I-SPY 2, overseeing the processes for FDA-IDE biomarker usage and qualifying biomarker companion diagnostic testing. She served 2010-2014 as Board member of the American Association of Cancer Research. She has over 230 peer-reviewed scientific articles and is co-inventor of 6 patents. Dr. van 't Veer received the 2007 European Society of Medical Oncology (ESMO) life-time achievement award for translational research in breast cancer and the prestigious European Union Women Innovator Award, 2nd prize in 2014. Dr. van ‘t Veer received undergraduate training in biology and a master of science in molecular oncology at the University of Amsterdam. She earned her PhD in Medicine at the University of Leiden as well as two postdoctoral fellowships, first at the Cancer Center of Harvard Medical School and Massachusetts General Hospital in Boston followed by the Division of Molecular Carcinogenesis at The Netherlands Cancer Institute.


 Speaker Profile

Ph.D., Vice President, Global Medical Epidemiology & Big Data Analysis, Pfizer Inc.

Biography
Christopher P. Boone has a career-long history as a dynamic, innovative thought leader and a public voice on the power of real-world data and health informatics and its ability to radically transform the U.S. health care delivery system from a healthcare quality and clinical research perspective. Boone currently serves as the Vice President and Global Medical Epidemiology and Big Data Analysis Lead at Pfizer, an adjunct professor at New York University’s Robert F. Wagner Graduate School of Public Service, an active board member of several influential organizations, and a co-founder of a few start-up companies. Most recently, he served as the Vice President of Real-World Data & Analytics at Pfizer. Boone has been recognized as a 2019 Top 100 Innovator in Data & Analytics, a 2018 Emerging Pharma Leader by Pharmaceutical Executive, and a 2017 Top 40 Under 40 in Minority Health Honoree by the National Minority Quality Forum.


 Speaker Profile

General Manager, Information Ventures, Quest Diagnostics

Biography
David joined Quest Diagnostics in 2015 as the General Manager, Information Ventures. In this position David and his team have been focused on advancing Quest’s strategy, solutions and partnerships in the area of clinical informatics. Powered by a clinical data repository with over 48 billion lab results, connectivity to half of the country’s physicians and hospitals via over 650 EMR interfaces, over 400,000 patient touch points a day, and broad geographic reach via over 2000 Patient Service Centers and 15,000 mobile care professionals, Information Ventures is delivering analytics solutions across the care and therapeutic continuums. David has more than 25 years of experience in healthcare technology innovation with a number industry leading companies, from the life science research bench to the patient’s bedside. His positions of increasing responsibility include serving as Vice President of Marketing at both Philips Healthcare and Becton Dickinson, Chief Marketing Officer at GE Healthcare – Patient Monitoring Solutions, General Manager at GE Healthcare - Patient Parameters Segment, and Senior Vice President of Marketing and Operations at Convergence Medical Devices. David has also been involved in a number of start-up companies in healthcare and technology. David earned an MBA from Northeastern University’s High Technology Management program, an MA in Communications from Emerson College and a BA from Vassar College.